Wed, April 15, 2020

Matthew Harrison Maintained (SRPT) at Buy with Decreased Target to $172 on, Apr 15th, 2020

Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $173 to $172 on, Apr 15th, 2020.

Matthew has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Matthew


  • Difei Yang of "Mizuho" Initiated at Strong Buy and Held Target at $183 on, Tuesday, March 31st, 2020
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Friday, March 27th, 2020
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $160 on, Friday, February 28th, 2020
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $217 on, Thursday, February 27th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $200 on, Monday, December 23rd, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $192 on, Friday, December 20th, 2019